Schedules

Know the
Target Audience


This event has many interactive sessions on Oncology, Hematology and Radiation Oncology
various diagnostic and therapeutic advancements which would focus on the recent trends in the
field and would pave way for more research in the field

  • Oncologists
  • Researchers
  • Academicians
  • Research Scholars
  • Students
  • Geneticists
  • Nurse Practitioners
  • Industrialists
  • Radiologists
  • Biologists
  • Radiation oncologists
  • Radiation physicists
  • Dosimetrists
  • Radiation therapists
  • Medical oncologists
  • Radiation oncology
  • administrators
  • Surgical Oncologists
  • Radiation therapists
  • Radiation oncology nurses
  • Diagnostic radiologists
  • All other health professionals involved in the field of Oncology, Hematology and Radiation
    Oncology

Know the
Event Tracks


  • Breast cancers
  • Hematology
  • Palliative Care
  • Physics
  • CNS Cancers

  • Gynecological Cancers

  • Lung Cancers

  • GU Cancers

  • GI Cancers

  • Head & Neck Cancers

SCHEDULE DETAILS
Scientific Program ( Agenda )





07:00 AM – 08:00 AM
Registration

Registration



08:00 AM – 08:05 AM
Opening Remarks

Opening Remarks

Chair Persons: Abdullah Al Zahrani, Abdulsalam Al Najjar, Shawqi Bazarbashi, M Rahal.



GI Cancer Session

GI Cancer Session



08:05 AM – 08:20 AM
Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).

Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).

Dr. Riechelmann Rachel



08:20 AM – 08:35 AM
FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer.

FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer.

Dr. Mohamed Salem



08:35 AM – 08:50 AM
Pembrolizumab With or Without Chemotherapy Versus Chemotherapy in Advanced G/GEJ Adenocarcinoma: The Phase 3, KEYNOTE-062 Study

Pembrolizumab With or Without Chemotherapy Versus Chemotherapy in Advanced G/GEJ Adenocarcinoma: The Phase 3, KEYNOTE-062 Study

Dr. Hafez Halwani



8:50 AM – 11:00 AM
Opening Ceremony

Opening Ceremony



11:00AM – 11:20 AM
Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.

Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.

Dr. Mohamed Salem



11:20 AM – 11:40 AM
APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.

APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.

Dr. Riechelmann Rachel



11:40 AM – 12:00 PM
Discussion

Discussion



(12:00 PM – 01:00 PM)
Prayer and Lunch

Prayer and Lunch



Breast Cancer Session

Breast Cancer Session

Chair Persons: Ahmed Abdulwarith, Dahish Ajarim, Ahmed Alfaraj, Huda Abdulkareem.



01:00 PM – 01:20 PM
SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).

SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).

Dr. Ahmed Saadelddin



01:20 PM – 01:40 PM
Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.

Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.

Dr. Omalkhair



01:40 PM – 02:00 PM
IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).

IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).

Dr. Adhar Alsayed



02:00 PM – 02:20 PM
Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.

Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.

Dr, Meteb Alfoheidi



(02:20 PM – 02:35 AM)
Discussion

Discussion



(02:35 PM – 02:45 PM)
Coffee Break

Coffee Break



Lung Cancer Session

Lung Cancer Session

Chair Persons: Essam Murshid, Majed Alothman, Mohammed Al Qarni, Hadi Almutairi



02:45 PM – 03:05 PM
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

Dr. Hamed Alhussaini



03:05 PM – 03:25 PM
Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.

Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.

Dr. Khalid Alsaleh



03:25 PM – 03:45 PM
RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Dr. Turki Alfaye



03:45 PM – 04:05 PM
ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC.

ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC.

Dr. A Jazieyah



(04:05 PM – 04:20 PM)
Discussion

Discussion



(04:20 PM – 04:30 PM)
Coffee Break

Coffee Break



GU Cancer Session

GU Cancer Session

Chair Persons: Amin Tijani, Abdullah Al Tuwairqi, Khalid Bawazeer, Mubarak Almansour.



04:30 PM – 04:50 PM
Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.

Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.

Dr. Abdalluh Alsharm



04:50 PM – 05:10 PM
First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

Dr. Rola Mufti



05:10 PM – 05:30 PM
Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).

Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).

Dr. Emad Tashkandi



05:30 PM – 05:50 PM
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.

Dr. Nedal Bukhari



(05:50 PM – 06:05 PM)
Discussion

Discussion



Closing Remarks

Closing Remarks




(07:00 AM – 08:00 AM)
Registration

Registration



Hematology Updates Session

Hematology Updates Session

Chair Persons: Basem Bayroti, Ahmed Alsaeed, Mosa Al Zahrani, Ahmed Alsageir.



08:00 AM – 08:20 AM
ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).

ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).

Dr. Solaf Khanfar



08:20 AM – 08:40 AM
A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).

A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).

Dr. Majed Alahmadi



08:40 AM – 09:00 AM
Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.

Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.

Dr. Turky Alwessaidi



09:00 AM – 09:20 AM
Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.

Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.

Dr. Ayman Hejazi



09:20 AM – 09:40 AM
Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD–) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities

Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD–) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities

Dr. Zayed Alzahrani



(09:40 AM – 10:05 AM)
Discussion

Discussion



(10:05 AM – 10:15 AM)
Coffee Break

Coffee Break



Sarcoma / Symptoms and Survivorship

Sarcoma / Symptoms and Survivorship

Chair Persons: Sameer Futaih, Mohammed Alghamdi, Fayez Alruwaili, Hafez Ghanem



10:15 AM – 10:35 AM
ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).

ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).

Dr. Ashwaq Alolayan



10:35 AM – 10:55 AM
STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma.

STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma.

Dr. Abdullah Alsuhail



10:55 AM – 11:15 AM
A randomized, double-blind, placebo-controlled phase III trial evaluating olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: J-FORCE Study.

A randomized, double-blind, placebo-controlled phase III trial evaluating olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: J-FORCE Study.

Dr. Abdullah Alsuhail



11:15 AM – 11:35 AM
Effects of exercise on cancer-related fatigue and muscular strength in patients with breast cancer.

Effects of exercise on cancer-related fatigue and muscular strength in patients with breast cancer.

Dr. Abdulaziz Aljuhani



(11:35 AM – 11:45 AM)
Discussion

Discussion



(11:45 AM – 01:00 PM)
Prayer and Lunch

Prayer and Lunch



Breast Cancer/GYN Session

Breast Cancer/GYN Session

Chair Persons: Abdul Aziz Al Hamad, Abdurrahman Al Shehri, Tawfeeq Tawfeeq, Jameelah Azhari.



01:00 PM – 01:20 PM
Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.

Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.

Dr. Shmidt



01:20 PM – 01:40 PM
Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM).

Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM).

Dr. Shmidt



01:40 PM – 02:00 PM
Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.

Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.

Dr. Hafez Halwani



02:00 PM – 02:20 PM
A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG oncology trial.

A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG oncology trial.

Dr. Shady Khayat



(02:20 PM – 02:45 PM)
Discussion

Discussion



(02:45 PM – 02:55 PM)
Coffee Break

Coffee Break



CNS / Melanoma / Head and Neck Session

CNS / Melanoma / Head and Neck Session

Chair Persons: Ahmed Alwabari, Ibraheem Madkhali, Majed Aljahel, Ahmed Badeeb.



02:55 PM – 03:15 PM
Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial.

Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial.

Dr. Marwan Alhujaili



03:15 PM – 03:35 PM
Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).

Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).

Dr. Faisal Azam



03:35 PM – 03:55 PM
Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial.

Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial.

Dr. Ahmed Alshehri



03:55 PM – 04:15 PM
Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Dr. Riyadh Dada



(04:15 PM – 04:40 PM)
Discussion

Discussion



Closing Remarks

Closing Remarks






BUY TICKET

Physicians

Physicians

SAR250

1000/1000

Buy Ticket


Physicians
Non-Physicians and Students

Non-Physicians and Students

SAR200

1000/1000

Buy Ticket


Non-Physicians and Students

Sponsor
Why Sponsor With Us



Contact us for sponsorship : sponsor@oncologyevent.com
× How can I help you?